Laitman Yael, Ries-Levavi Liat, Berkensdadt Michal, Korach Jacob, Perri Tamar, Pras Elon, Friedman Eitan
Susanne Levy Gertner Oncogenetics Unit,The Danek Gertner Institute of Human Genetics, and theGyneco-oncology Department,Chaim Sheba Medical Center, Tel-Hashomer and the Sackler School of Medicine, Tel-Aviv University,Ramat AvivIsrael.
Genet Res (Camb). 2014 Oct 8;96:e11. doi: 10.1017/S0016672314000147.
Premature ovarian failure and diminished ovarian reserve have been noted both in female BRCA1/BRCA2 mutation carriers and in carriers of the Fragile X syndrome FMR1 gene CGG repeat size premutation. Based on the observation that BRCA mutation carriers do not harbour long CGG repeats in the FMR1 gene, it was hypothesized that BRCA-associated premature ovarian failure is mediated via FMR1. To test this notion, we evaluated the distribution of constitutional FMR1 genotypes in 188 BRCA1/BRCA2 mutation-positive Jewish Ashkenazi women and 15 708 female, mostly Ashkenazi controls in Israel. BRCA1/BRCA2 mutation carriers displayed a unique distribution of FMR1 genotypes compared with controls (p = 0·018) with a prominence of the shorter CGG alleles (<26 repeats). There was no allele size distribution differences within BRCA carriers when comparing cancer free (n = 95) and breast cancer affected women (n = 93) (p = 0·43). In conclusion, BRCA mutation carriers exhibit a distinct CGG FMR1 repeat size pattern compared with the general population, but it is unlikely to account for the reported diminished ovarian reserve or act as a modifier breast cancer gene in BRCA mutation carriers.
在携带BRCA1/BRCA2突变的女性以及脆性X综合征FMR1基因CGG重复序列大小处于前突变状态的携带者中,均已观察到卵巢早衰和卵巢储备功能减退的情况。基于BRCA突变携带者在FMR1基因中不存在长CGG重复序列这一观察结果,有人提出假说,认为BRCA相关的卵巢早衰是通过FMR1介导的。为了验证这一观点,我们评估了188名携带BRCA1/BRCA2突变的犹太裔阿什肯纳兹女性以及以色列15708名女性(大多数为阿什肯纳兹对照人群)中FMR1基因组成型基因型的分布情况。与对照人群相比,BRCA1/BRCA2突变携带者的FMR1基因型分布具有独特性(p = 0.018),较短的CGG等位基因(<26次重复)更为突出。在比较未患癌症的女性(n = 95)和患乳腺癌的女性(n = 93)时,BRCA携带者内部的等位基因大小分布没有差异(p = 0.43)。总之,与普通人群相比,BRCA突变携带者表现出独特的CGG FMR1重复序列大小模式,但这不太可能解释所报道的卵巢储备功能减退,也不太可能在BRCA突变携带者中作为乳腺癌修饰基因发挥作用。